Acute Myocardial Infarction (AMI) remains a huge burden across the U.S. care continuum for patients and healthcare providers. Over 7 million Americans present to the ED annually with chest pain and 1 in 10 of these patients are diagnosed with an AMI.
The Atellica IM TnIH assay can be used to aid in offering rapid and accurate detection of AMI, helping lead to a faster diagnosis (versus contemporary Troponin assays); it can now also assist clinicians to identify future death and cardiovascular event risk based on the new prognosis indication for use. This assay is the first and only in the U.S. so far to include prognosis as part of the new, expanded intended use.
Key Topics
- Learn about the clinical significance of High-Sensitivity Troponin testing to support acute and long-term cardiac care of patients.
- Learn from real-life examples/case-studies and nuances in clinical outcomes based on patient history, risk-factors, clinical diagnosis protocol within institutions, etc.
- Learn about the new prognosis claim along with supporting data for different patient populations (with and without history of MACE, etc.) and how prognosis is utilized in healthcare systems.
- Learn from both a clinician and laboratorian perspective in the importance of coordinated long-term cardiac care management in patients presenting in the ED with suspected AMI.
Moderator
Dr. Melanie Pollan has over 20 years of experience serving the laboratory in several roles including technologist, consultant, and administrator. She is the Director of Scientific & Clinical Affairs as well as the Collaborations Manager for North America.
Dr. Pollan has a BS in Clinical Laboratory Science, a Master of Science, and a Doctor of Philosophy in Clinical Health Science at the University of MS Medical Center- emphasis in pathophysiology, and conducted research on sustained drug delivery systems and the impact of androgens on the male reproductive system. Dr. Pollan demonstrates her passion for laboratory medicine, daily, by supporting laboratorians and clinicians with education in multiple diagnostic disciplines, including cardiac, infectious disease, diabetes, sepsis, and endocrinology.
Speakers
Dr. Alan H. B. Wu
Alan H.B. Wu, Ph.D., is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital Professor of Lab Medicine, University of California, San Francisco. 聽He received B.S. degrees in chemistry and biology at Purdue University and a Ph.D. degree in analytical chemistry at the University of Illinois. 聽He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. 聽He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. His research interests include clinical toxicology, cardiac biomarkers, and point-of-care testing. 聽Dr. Wu has over 500 publications in peer-reviewed journals. 聽He has also written eight paperback books consisting of short stories designed to promote the value of the clinical laboratory to the general public. Recently he has launched a social media campaign to further expose lab medicine to students.
Dr. Christopher DeFilippi
Dr. Chris DeFilippi joined the Inova Heart and Vascular Institute as the Vice-Chair of Academic Affairs in 2016. Previously he was an Associate Professor of Medicine at the University of Maryland. He also serves as the Inova site Principal Investigator for the NIH funded Clinical and Translational Science Awards (CTSA) Program with University of Virginia and Virginia Tech. In his oversight of clinical research he has built IHVI to be a national leader in site based research. Under his mentorship in 2020 two junior IHVI attending received NHLBI K23 award and another received an R01. He serves on the Editorial boards of Circulation, JACC and JACC: Heart Failure. He is an Associate Editor for the Journal of Applied Laboratory Medicine. His research is focused on evaluating in-vitro diagnostics and proteomics discovery for diagnosis, prognosis, and therapy guidance across the spectrum of health from detection of preclinical cardiovascular disease to diagnosis and treatment in the critically ill.
